期刊文献+

低剂量沙利度胺联合常规化疗治疗多发性骨髓瘤临床分析 被引量:8

下载PDF
导出
摘要 目的探讨低剂量沙利度胺联合常规化疗治疗多发性骨髓瘤的疗效及临床分析。方法2010年02月至2012年02月期间,我院诊治的60例多发性骨髓瘤患者,给予低剂量沙利度胺联合常规化疗治疗,对其临床症状改善情况、临床疗效,以及不良反应,进行观察和分析。结果低剂量沙利度胺联合常规化疗,治疗3个月后,60例多发性骨髓瘤患者的临床症状均得到了明显改善,31例完全缓解(51.67%),12例部分缓解(20.00%),10例进步(16.67%),7例无效(11.67%),其治疗的总有效率为88.34%。有9例患者出现皮疹、便秘,以及轻度嗜睡症状,经过对症治疗后,得到缓解。15例患者出现以白细胞和血小板减少为主的骨髓抑制,给予相应治疗后,症状好转。结论对于多发性骨髓瘤患者,低剂量沙利度胺联合常规化疗的疗效显著,并且不良反应少,值得临床推广。
作者 姜祖光
出处 《中国实用医药》 2012年第22期146-147,共2页 China Practical Medicine
  • 相关文献

参考文献6

二级参考文献46

  • 1徐茂忠,徐昕,赵钰.低剂量沙利度胺联合化疗治疗难治性多发性骨髓瘤7例[J].中国交通医学杂志,2006,20(2):147-148. 被引量:2
  • 2岑海燕,陈钰.反应停联合VAD方案治疗多发性骨髓瘤的疗效[J].中国肿瘤生物治疗杂志,2006,13(5):384-386. 被引量:3
  • 3Blade J, Samson D, Recce D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantion. Myeloma Subcommittee of the EBMT. European Group For Blood and Marrow Transplant[J]. Br J Haematol, 1998, 102(5): 1115-1123.
  • 4Fermand JP, Katsahian S ,Divine M, et al. High dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55-65 years: long-term results of randomized control trial from the Group Myeloma-Autograffe[J]. J Clin Lncol, 2005, 23(36): 9227-9233.
  • 5Hus M, Dmoszynska A, Manko, J, et al. An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma[J]. Br J Cancer, 2004, 91 (11): 1873-1879.
  • 6Antonio P, Sara B, Tommas C, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisune alone in elderly patients with multiple myeloma: randomized controlled trial[J]. Lancet, 2006, 367(9513): 825-831.
  • 7Shajio K, Vincent RS. Thalidomide and lenalidomide in the treatment of multiple myeloma[J]. Eur J Cancer, 2006, 42(11): 1612-1622.
  • 8Michel A, Jean-luc H, Serge L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma [J]. Blood, 2006, 108(15): 3289-3294.
  • 9Myers B,Grimley C,Dolan G.Thalidomide and low-dose dexamethasone in myeloma treatment[J].Br J Haematol,2001,114:245 -246.
  • 10Bohle AS,Kalthoff H.Molecular mechanisms of tumor metastasis and angiogenesis[J].Langenbecks Arch Surg,1996,384:133-140.

共引文献18

同被引文献80

  • 1高津,傅晋翔,张宏.T-VAD和VAD方案治疗多发性骨髓瘤的疗效观察[J].中国血液流变学杂志,2008,18(1):75-77. 被引量:6
  • 2唐雪娟,任莉.低剂量沙利度胺联合常规化疗治疗多发性骨髓瘤的临床分析[J].中国生化药物杂志,2014,34(4):113-115. 被引量:21
  • 3邵蓉,蒋正华,黄泰康.医疗机构涉药人员执业风险防范与规避[J].中国药房,2007,18(28):2163-2164. 被引量:25
  • 4American Society of Hospital Pharmacists. ASHP statement on the use of medications for unlabeled uses[J]. Am J Hosp Pharm, 1992, 49 (8): 2006-2008.
  • 5Herring C, McManus A, Weeks A. Off-label prescribing during pregnancy in the UK:an analysis of 18, 000 prescriptions in Liver- pool Women's Hospital[J]. Int J Pharm Pract, 2010, 18(4): 226- 229.
  • 6Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries[J]. BMJ, 2000, 320(7227): 79-82.
  • 7Hames A, Wynne HA. Unlicensed and off-label drug use in elderly people[J]. Age Ageing, 2001, 30(6): 530-531.
  • 8Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians[J]. Arch Intern Med, 2006, 166(9): 1021-1026.
  • 9Eastman P. Reimbursement policies discourage off-label drug use[J]. Oncology Times, 2005, 27(20): 8-10.
  • 10Olsson J, Kimland E, Pettersson S, et al. Paediatric drug use with focus on off-label prescriptions in Swedish outpatient eare-a nation wide study[J]. Acta Paediatr, 2011, 100(9): 1272-1275.

引证文献8

二级引证文献108

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部